CORRECTED-Sanofi to acquire US biotech Dynavax for $2.2 billion

Dec 24 (Reuters) - French drugmaker Sanofi SASY.PA has entered into an agreement to acquire U.S. vaccines company Dynavax Technologies Corporation DVAX.O for around $2.2 billion (1.87 billion euros), it said on Wednesday.

Under the terms disclosed, Sanofi will pay $15.50 per share in cash, representing a 39% premium over Dynavax's Tuesday closing price and a 46% premium over its three-month volume-weighted average price.

Sanofi expects to complete the acquisition in the first quarter of 2026 and says it will use available cash. The deal will not affect its 2025 financial outlook, it adds.

(1 euro = $1.1789)